Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)
Carcinoma, Renal Cell
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 263 (final count)
- Started
- Dec 17, 2020
- Main results expected
- Jul 23, 2026
- Fully finished
- Jul 23, 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Safety Lead-in Phase: Number of participants who experience one or more dose-limiting toxicities (DLTs)
Measured over: Up to ~21 days
Safety Lead-in Phase: Number of participants who experience one or more adverse events (AEs)
Measured over: Up to ~21 days
Safety Lead-in Phase: Number of participants who discontinue study treatment due to an AE
Measured over: Up to ~21 days
Efficacy Phase: Number of participants who experienced DLTs
Measured over: Up to ~21 days
Efficacy Phase: Number of participants who experience one or more AEs
Measured over: Up to ~56 months
Efficacy Phase: Number of participants who discontinue study treatment due to an AE
Measured over: Up to ~56 months
Efficacy Phase: Objective response rate (ORR)
Measured over: Up to ~56 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04626518 · record last updated 2026-09-25 · checked 2026-11-09 15:47 UTC